Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more
Painreform Ltd (PRFX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.117x
Based on the latest financial reports, Painreform Ltd (PRFX) has a cash flow conversion efficiency ratio of -0.117x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-991.00K) by net assets ($8.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Painreform Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Painreform Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Painreform Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Painreform Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zelira Therapeutics Limited
OTCQB:ZLDAF
|
0.425x |
|
Archies Limited
NSE:ARCHIES
|
0.015x |
|
Rich Goldman Holdings Limited
F:MRU3
|
-0.033x |
|
SQX Resources Ltd
AU:SQX
|
0.000x |
|
TinOne Resources Inc.
OTCQB:TORCF
|
-0.045x |
|
Mistral Patrimonio Inmobiliario SOCIMI SA
MC:YMPI
|
0.035x |
|
T-MOBILE US (TM5.SG)
STU:TM5
|
0.096x |
|
Triboron International AB (publ)
ST:TRIBO-B
|
0.068x |
Annual Cash Flow Conversion Efficiency for Painreform Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Painreform Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.82 Million | $-12.62 Million | -6.919x | -649.96% |
| 2023-12-31 | $7.24 Million | $-6.68 Million | -0.923x | -57.43% |
| 2022-12-31 | $11.02 Million | $-6.46 Million | -0.586x | -61.72% |
| 2021-12-31 | $18.08 Million | $-6.55 Million | -0.362x | -135.56% |
| 2020-12-31 | $16.62 Million | $-2.56 Million | -0.154x | -242.03% |
| 2019-12-31 | $-5.62 Million | $-609.00K | 0.108x | -23.97% |
| 2018-12-31 | $-4.46 Million | $-635.00K | 0.142x | -40.57% |
| 2017-12-31 | $-3.63 Million | $-870.00K | 0.240x | -- |